SWI3 Antibody

What is SWI3 and why is it important in cellular research?

SWI3 is a critical component of the SWI/SNF chromatin remodeling complex that plays a unique role in regulating cellular processes, particularly respiration. Recent experimental evidence has established that SWI3 functions as a key regulator of respiration genes, making it particularly important for understanding cellular bioenergetics. SWI3 has two human homologues, BAF155 and BAF170, which contain conserved functional domains. Research has demonstrated that dysregulation of these proteins is associated with a wide array of human diseases, including cancer, neurological diseases, and diabetes, highlighting SWI3's significance in translational research .

How are SWI3 antibodies typically generated for research applications?

SWI3 antibodies are typically generated by immunizing animals (commonly rabbits) with purified SWI3 protein or synthetic peptides representing specific regions of SWI3. For research-grade antibody production, affinity purification techniques are employed to isolate SWI3-specific antibodies from crude antiserum. The process involves equilibrating affinity-purified SWI3 antibody with protein A-Sepharose beads to create immune complexes that can be used for various applications . The quality and specificity of SWI3 antibodies can be validated through Western blotting against wild-type and SWI3-knockout cell extracts, ensuring that the antibody specifically recognizes the target protein.

What is the difference between polyclonal and monoclonal SWI3 antibodies?

Polyclonal SWI3 antibodies:

• Derived from multiple B-cell lineages, recognizing different epitopes of the SWI3 protein

• Typically provide higher sensitivity due to multiple epitope recognition

• More robust to protein denaturation in techniques like Western blotting

• Show batch-to-batch variability

Monoclonal SWI3 antibodies:

• Derived from a single B-cell clone, recognizing only one epitope

• Provide higher specificity and lower background

• Show minimal batch-to-batch variability

• May be less sensitive than polyclonal antibodies

For co-immunoprecipitation of SWI/SNF complexes, monoclonal antibodies may be preferred for their high specificity, while polyclonal antibodies might be better suited for detection of SWI3 in Western blot applications where sensitivity is paramount.

How can I use SWI3 antibodies to study the SWI/SNF complex through immunoprecipitation?

SWI3 antibodies are valuable tools for immunoprecipitating the entire SWI/SNF complex due to SWI3's stable interactions with other complex components. Based on established protocols, the procedure involves:

• Preparing cell lysates under non-denaturing conditions to preserve protein-protein interactions

• Incubating 4 μl of affinity-purified SWI3 antibody with 20 μl of 50% protein A-Sepharose beads at 4°C for 30 minutes

• Adding the antibody-bead mixture to the cell lysate and incubating for 2-4 hours

• Washing the immune complexes thoroughly to remove non-specific binding

• Eluting the complex using either SDS sample buffer for direct analysis or gentle elution with glycine buffer (pH 2.3) for functional studies

This approach enables co-precipitation of the entire multi-protein complex, including SWI1/ADR6, SWI2/SNF2, SNF5, and SNF6 proteins, which collectively form a functional unit .

What are the optimal conditions for using SWI3 antibodies in Western blotting?

For optimal Western blotting results with SWI3 antibodies, consider these key methodological parameters:

When detecting SWI3, it's important to note that it migrates at approximately 130 kDa on SDS-PAGE gels. Additional bands at 155 kDa may represent modified or associated forms of the protein that may be present in the SWI complex .

How can I use SWI3 antibodies to investigate the role of SWI3 in regulating respiration?

To investigate SWI3's role in respiration regulation, researchers can employ the following approaches using SWI3 antibodies:

• Chromatin Immunoprecipitation (ChIP): Use SWI3 antibodies to identify genomic regions bound by SWI3, particularly promoters of respiration genes

• Co-Immunoprecipitation followed by Mass Spectrometry: Identify proteins interacting with SWI3 under different respiratory conditions (aerobic vs. anaerobic)

• Immunofluorescence microscopy: Track SWI3 localization changes in response to oxygen level fluctuations

• Western blotting: Compare SWI3 protein levels and post-translational modifications between wild-type cells and respiratory-deficient mutants

These approaches, combined with functional assays such as oxygen consumption measurements and analysis of respiratory chain complex levels, can provide insights into how SWI3 regulates respiratory gene expression. Research has shown that deletion of SWI3 leads to increased oxygen consumption and elevated levels of mitochondrial respiratory chain complexes, suggesting SWI3 plays a repressive role in respiration gene expression under certain conditions .

How do SWI3 antibodies help distinguish between haem-dependent and haem-independent functions of SWI3?

SWI3 plays distinct roles in haem-dependent and haem-independent regulation of respiration genes. Using SWI3 antibodies in chromatin immunoprecipitation (ChIP) assays under varying haem conditions provides critical insights into these mechanisms:

• Comparative ChIP analysis: Perform ChIP with SWI3 antibodies in haem-sufficient and haem-deficient cells to identify differential binding patterns to promoter regions of respiration genes

• Reporter assay validation: Use reporter constructs containing respiration gene promoters and correlate SWI3 binding (detected by ChIP) with promoter activity levels

• Differential complex analysis: Immunoprecipitate SWI3 under haem-sufficient and haem-deficient conditions to identify changing interaction partners

Research has demonstrated that SWI3 strongly affects haem/oxygen-dependent activation of respiration gene promoters, while SWI2 primarily affects the basal, haem-independent activities of these promoters. In Δswi3 cells, the activities of respiration gene reporters were higher than in haem-deficient parent cells but not as high as in haem-deficient Δswi2 cells, indicating distinct regulatory roles .

How can I use SWI3 antibodies to study the differences between yeast SWI3 and its human homologues BAF155 and BAF170?

To investigate the functional conservation and differences between yeast SWI3 and its human homologues BAF155 and BAF170, researchers can employ the following approaches:

• Cross-reactivity testing: Determine whether SWI3 antibodies cross-react with human BAF155/BAF170 by Western blotting against both yeast and human cell extracts

• Comparative immunoprecipitation: Use species-specific antibodies to isolate yeast SWI3 complexes and human BAF155/BAF170 complexes, followed by proteomic analysis to identify conserved and distinct interaction partners

• Functional complementation studies: Express human BAF155/BAF170 in Δswi3 yeast cells and use SWI3 antibodies to confirm expression, then assess functional rescue of respiration phenotypes

• Domain-specific antibodies: Generate antibodies against conserved domains to study their specific functions across species

Research has shown that like yeast SWI3, human BAF155 and BAF170 are preferentially associated with genes encoding oxidative phosphorylation functions. RNAi knockdown experiments confirmed that these human homologues regulate respiration in HeLa cells, demonstrating functional conservation across species despite evolutionary distance .

How do post-translational modifications affect SWI3 function and antibody recognition?

Post-translational modifications (PTMs) of SWI3 can significantly impact both its biological function and antibody recognition:

To address these challenges when studying SWI3 modifications:

• Use multiple antibodies targeting different epitopes of SWI3

• Employ modification-specific antibodies for direct detection

• Combine immunoprecipitation with mass spectrometry to identify modifications

• Verify findings using mutagenesis of potential modification sites

Silver staining analysis of immunoprecipitated SWI/SNF complexes has revealed multiple bands representing different forms of complex components, suggesting the presence of post-translationally modified species that may have distinct functions in the regulation of respiration genes .

What are common issues with SWI3 antibody immunoprecipitation and how can they be resolved?

Researchers often encounter several challenges when performing immunoprecipitation with SWI3 antibodies:

For optimal SWI3 complex immunoprecipitation, equilibrate affinity-purified SWI3 antibody (4 μl) with protein A-Sepharose beads (20 μl of 50% solution) at 4°C for 30 minutes before adding to cell lysates. This approach has been demonstrated to efficiently isolate intact SWI/SNF complexes containing SWI3 along with other components such as SWI1/ADR6, SWI2/SNF2, SNF5, and SNF6 .

How can I validate the specificity of a new SWI3 antibody?

Validating the specificity of a new SWI3 antibody is critical for reliable experimental results. A comprehensive validation approach should include:

• Western blot analysis:

  • Compare wild-type cells with Δswi3 knockout cells/tissues

  • Check for a single band at the expected molecular weight (~130 kDa for SWI3)

  • Test competing peptide blocking to confirm epitope specificity

• Immunoprecipitation validation:

  • Perform IP followed by Western blot with a different SWI3 antibody

  • Confirm co-immunoprecipitation of known SWI3 interaction partners (SWI1/ADR6, SWI2/SNF2)

  • Perform reverse IP with antibodies against known partners

• Immunofluorescence specificity:

  • Compare staining patterns in wild-type versus Δswi3 cells

  • Perform peptide competition assays

  • Verify subcellular localization matches known distribution

• Cross-reactivity assessment:

  • Test against recombinant SWI3 and related proteins

  • Evaluate potential cross-reactivity with the human homologues BAF155 and BAF170

Experimental evidence has shown that proper validation ensures antibodies can specifically identify SWI3 as part of the multi-protein complex with apparent molecular mass of 130 kDa on SDS-PAGE gels .

What considerations are important when designing multi-tiered immunoassays involving SWI3 antibodies?

When designing multi-tiered immunoassays for SWI3 detection and characterization, researchers should consider several important factors:

• Assay architecture:

  • Initial screening assay for SWI3 presence

  • Confirmatory assay with increased stringency

  • Characterization assays for specific modifications or interactions

• Controls and standardization:

  • Include positive controls (purified SWI3 protein)

  • Use negative controls (Δswi3 extracts)

  • Establish cut-off values for positive/negative determination

• Data structure and analysis:

  • Create hierarchical data structures to track samples through multiple assay tiers

  • Map raw data to standardized formats for consistent analysis

  • Apply appropriate statistical methods for each tier

• Validation metrics:

  • Determine sensitivity and specificity for each assay tier

  • Establish reproducibility parameters

  • Set acceptance criteria for moving samples between tiers

This multi-tiered approach is similar to the ADA testing scheme described in pharmaceutical research, where samples undergo screening, confirmation, and characterization steps. For SWI3 research, this approach ensures reliable identification of true SWI3-positive samples while minimizing false positives and providing detailed characterization of positive samples .

How can SWI3 antibodies be used to investigate the role of SWI3 in disease models?

SWI3 antibodies are valuable tools for investigating the role of SWI3 and its homologues in disease models, particularly given the association between dysregulation of cellular bioenergetics and common human diseases:

• Cancer research applications:

  • Immunohistochemistry to compare SWI3/BAF155/BAF170 expression in tumor versus normal tissues

  • ChIP-seq to identify altered binding patterns in cancer cells

  • Co-IP to detect aberrant complex formation in tumorigenic processes

• Neurological disease models:

  • Western blotting to quantify SWI3 homologue levels in brain tissue samples

  • Immunofluorescence to track subcellular localization changes in disease states

  • Pulldown assays to identify disease-specific interaction partners

• Metabolic disorders:

  • ChIP analysis to examine SWI3 binding to metabolic gene promoters in diabetes models

  • Proximity ligation assays to visualize SWI3 interactions with metabolic regulators

  • Sequential IP to isolate disease-specific subcomplexes

Research has established that dysregulation of SWI3 and its homologues BAF155/BAF170 is associated with cancer, neurological diseases, and diabetes, making SWI3 antibodies crucial tools for investigating the molecular basis of these conditions .

What are the considerations for using SWI3 antibodies in ChIP-seq experiments?

ChIP-seq with SWI3 antibodies provides genome-wide insights into SWI3 binding patterns, but requires careful optimization:

When analyzing ChIP-seq data for SWI3, researchers should focus on identifying binding patterns to respiration gene promoters under different oxygen conditions, as SWI3 is known to respond to both hypoxia and reoxygenation, which influences its genomic localization and regulatory function. Comparative analysis between SWI3 and other respiratory regulators like Hap2/3/4/5, Mot3, and Rox1 can provide insights into the unique role of SWI3 in respiratory gene regulation .

How can I combine SWI3 antibodies with proximity labeling techniques to identify novel interaction partners?

Integrating SWI3 antibodies with proximity labeling techniques offers powerful approaches to discover novel interaction partners:

• BioID-based approach:

  • Generate a BioID-SWI3 fusion protein

  • Use SWI3 antibodies to confirm proper expression and localization

  • Identify biotinylated proteins after streptavidin pulldown

  • Validate interactions by conventional co-IP with SWI3 antibodies

• APEX2-based approach:

  • Create APEX2-SWI3 fusion constructs

  • Confirm functional activity using SWI3 antibodies

  • Perform peroxidase-catalyzed biotinylation in living cells

  • Compare biotinylated interactome with conventional SWI3 antibody pulldowns

• Split-BioID system:

  • Fuse SWI3 to one half of split-BioID

  • Use candidate proteins fused to complementary half

  • Confirm proximity-induced biotinylation

  • Validate with traditional SWI3 antibody co-IP

These approaches can reveal transient or context-specific interactions that might be missed by conventional immunoprecipitation. When applying these techniques to study SWI3's role in respiration, researchers should consider performing experiments under different oxygen conditions, as SWI3 has been shown to respond to both hypoxia and reoxygenation, potentially engaging with different protein partners under these varying conditions .